Prescription medication · JAK Inhibitor (Topical)

ruxolitinib topical

Also sold as Opzelura. Opzelura treats mild to moderate atopic dermatitis (eczema) in adults and children 2 years and older.

Data updated 2026-05-15

$32.82
Brand price (NADAC)

ruxolitinib topical (Opzelura) is a prescription JAK Inhibitor (Topical). Opzelura treats mild to moderate atopic dermatitis (eczema) in adults and children 2 years and older.

Opzelura is a cream that contains ruxolitinib. It is used on the skin to treat certain skin conditions.

Verify with FDA → · CMS NADAC pricing →

Drug Pricing (NADAC)

Brand Price

$32.82/unit

Generic Available

No

INCYTE CORP

Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →

Compare with Another Drug →

What it does

Opzelura treats mild to moderate atopic dermatitis (eczema) in adults and children 2 years and older.

Common side effects

Common cold, Diarrhea, Bronchitis

Key warnings

Opzelura may increase your risk of serious infections, cancer, blood clots, and major heart problems.

The sections below are summarized in plain English from ruxolitinib topical's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.

How It Works

Opzelura contains a medicine called a Janus kinase (JAK) inhibitor. It works by blocking certain proteins in your body. These proteins are part of the process that causes skin inflammation and color loss.

Serious Warnings

Opzelura may increase your risk of serious infections, cancer, blood clots, and major heart problems. Contact your doctor immediately if you develop any signs or symptoms of an infection, such as fever, cough, or sore throat. Tell your doctor if you have ever had tuberculosis, as it could become active again. If you have a heart attack or stroke, stop using Opzelura.

Common Questions

Can I use Opzelura with other skin medicines?
Talk to your doctor before using Opzelura with other skin medicines, especially strong immunosuppressants.
How long does it take for Opzelura to work?
It may take several weeks to see improvement. If you do not see improvement after 8 weeks for eczema or 24 weeks for vitiligo, talk to your doctor.
Can I use Opzelura on any part of my body?
No, do not use Opzelura in your eyes, mouth, or vagina. Only use it on the affected skin areas.
What should I do if I get a skin infection while using Opzelura?
Tell your doctor right away if you think you have a skin infection.
Can children use Opzelura?
Yes, Opzelura can be used in children 2 years and older for eczema and 12 years and older for vitiligo.
Is it okay to smoke while using Opzelura?
No. Patients who are current or past smokers are at additional increased risk of major adverse cardiovascular events.
What are the symptoms of thrombosis?
Symptoms of thrombosis include pain and swelling in your legs, sudden chest pain, or shortness of breath.
Can I get a skin cancer from using Opzelura?
Yes, basal cell and squamous cell carcinoma have occurred. Perform periodic skin examinations during and following treatment.
What should I do if I have an active, serious infection?
Avoid use of OPZELURA in patients with an active, serious infection, including localized infections.
What should I do if I have a serious infection?
If a serious infection develops, interrupt OPZELURA until the infection is controlled.
What are the common side effects of ruxolitinib topical?
The registry lists Common cold, Diarrhea, Bronchitis, Ear infection, Increased eosinophil count among the most-reported FAERS reaction terms for ruxolitinib topical. These counts are not an individual symptom assessment.
What drug class is ruxolitinib topical?
ruxolitinib topical belongs to the JAK Inhibitor (Topical) drug class. It requires a prescription (Rx). Opzelura treats mild to moderate atopic dermatitis (eczema) in adults and children 2 years and older.
What pregnancy or breastfeeding source fields are listed for ruxolitinib topical?
The FDA label for ruxolitinib topical contains product-specific pregnancy or breastfeeding language. PlainMeds does not apply that source text to an individual.

Related Medications in JAK Inhibitor (Topical)

Other drugs grouped near ruxolitinib topical - same-class peers and common alternatives.

adapalene

Differin

Compare with ruxolitinib topical →

apremilast

Otezla

Apremilast (Otezla/Otezla XR) is a medicine that can help adults and children manage psoriatic arthritis and psoriasis.

Compare with ruxolitinib topical →

azelaic acid

Finacea, Azelex

Azelaic acid gel is a topical medicine that helps treat rosacea.

Compare with ruxolitinib topical →

benzoyl peroxide

Benzac, PanOxyl

Benzoyl peroxide is a topical medicine that fights germs on your skin.

Compare with ruxolitinib topical →

betamethasone

Diprosone, Luxiq

Betamethasone dipropionate cream is a strong steroid medicine used on the skin.

Compare with ruxolitinib topical →

Compare ruxolitinib topical vs adapalene side-by-side →

Medication Guides

Understanding Drug Interactions

How CYP450 enzymes, inhibitors, and inducers affect your medications

Generic vs Brand Name Drugs

FDA requirements, cost savings, and when the difference matters

Narrow Therapeutic Index Drugs

FDA bioequivalence and label-record context for narrow therapeutic index medicines

Common Drug Interactions

Dangerous medication combinations and how to protect yourself

Save on ruxolitinib topical

Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.

Check Prices on GoodRx →

Disclosure: This link may earn us a commission at no extra cost to you. See our terms.

What the FDA Data Shows for ruxolitinib topical

The FDA label for ruxolitinib topical (sold under brand names such as Opzelura) classifies it as a prescription-only medication in the JAK Inhibitor (Topical) class. Opzelura treats mild to moderate atopic dermatitis (eczema) in adults and children 2 years and older. Official labeling lists 19 commonly reported side effects, including Common cold, Diarrhea, Bronchitis.

Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. Voluntary reports accumulate over the lifetime of a drug and reflect wide-ranging clinical use. Interaction data is drawn directly from FDA-approved prescribing information. NADAC pricing from CMS.

Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.

Data Sources

Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).

FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.

Last updated: November 11, 2025

PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.

Read our methodology - how this data is sourced, computed, and verified.

Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.

All federal data sources used on this page